<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ophthalmology</journal-id><journal-title-group><journal-title xml:lang="ru">Офтальмология</journal-title><trans-title-group xml:lang="en"><trans-title>Ophthalmology in Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1816-5095</issn><issn pub-type="epub">2500-0845</issn><publisher><publisher-name>Ophthalmology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18008/1816-5095-2018-2S-261-267</article-id><article-id custom-type="elpub" pub-id-type="custom">ophthalmology-658</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРОЧЕЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OTHER</subject></subj-group></article-categories><title-group><article-title>Место ботокса в комплексном лечении патологии глазодвигательной системы (оптимальный «портрет» страбизмологического пациента для проведения хемоденервации)</article-title><trans-title-group xml:lang="en"><trans-title>Botox’s Place in the Complex Treatment of Oculomotor System Pathology (the Optimal “Portrait” of the Patient for the Chemodenervation)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5120-8360</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Плисов</surname><given-names>И. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Plisov</surname><given-names>I. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, заведующий 3-м офтальмологическим отделением,</p><p>ул. Колхидская, 10, Новосибирск, 630096</p></bio><bio xml:lang="en"><p>MD, Head of the 3rd ophthalmology department,</p><p>Kolkhidskaya str., 10, Novosibirsk, 630096</p></bio><email xlink:type="simple">plisov_rus@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черных</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Cherhykh</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, директор Новосибирского филиала,</p><p>ул. Колхидская, 10, Новосибирск, 630096</p></bio><bio xml:lang="en"><p>MD, professor, Head of the Novosibirsk Branch,</p><p>Kolkhidskaya str., 10, Novosibirsk, 630096</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Атаманов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Atamanov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>заведующий 7-м офтальмологическим отделением,</p><p>ул. Колхидская, 10, Новосибирск, 630096</p></bio><bio xml:lang="en"><p>Head of the 7th ophthalmology department,</p><p>Kolkhidskaya str., 10, Novosibirsk, 630096</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Анциферова</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Antsiferova</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, врач-офтальмолог 3-го офтальмологического отделения,</p><p>ул. Колхидская, 10, Новосибирск, 630096</p></bio><bio xml:lang="en"><p>PhD, ophthalmologist of the 3rd ophthalmology department,</p><p>Kolkhidskaya str., 10, Novosibirsk, 630096</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пущина</surname><given-names>В. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Pushchina</surname><given-names>V. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-офтальмолог 3-го офтальмологического отделения,</p><p>ул. Колхидская, 10, Новосибирск, 630096</p></bio><bio xml:lang="en"><p>Ophthalmologist of the 3rd ophthalmology department,</p><p>Kolkhidskaya str., 10, Novosibirsk, 630096</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Истомина</surname><given-names>Т. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Istomina</surname><given-names>T. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-офтальмолог поликлинического отделения,</p><p>ул. Немировича Данченко, 132/1, Новосибирск, 630087</p></bio><bio xml:lang="en"><p>Ophthalmologist of the polyclinic department,</p><p>Nemirovicha-Danchenko str., 132/1, Novosibirsk, 630087</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАУ «МНТК “Микрохирургия глаза” имени академика С.Н. Федорова» Министерства здравоохранения Российской Федерации, Новосибирский филиал</institution><country>Россия</country></aff><aff xml:lang="en"><institution>S.N. Fyodorov IRTC “Eye Microsurgery” FSAI of the Ministry of Health Care of the Russian Federation, Novosibirsk Branch</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Федеральный центр нейрохирургии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Neurosurgical Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>28</day><month>07</month><year>2018</year></pub-date><volume>15</volume><issue>2S</issue><fpage>261</fpage><lpage>267</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Плисов И.Л., Черных В.В., Атаманов В.В., Анциферова Н.Г., Пущина В.Б., Истомина Т.К., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Плисов И.Л., Черных В.В., Атаманов В.В., Анциферова Н.Г., Пущина В.Б., Истомина Т.К.</copyright-holder><copyright-holder xml:lang="en">Plisov I.L., Cherhykh V.V., Atamanov V.V., Antsiferova N.G., Pushchina V.B., Istomina T.K.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ophthalmojournal.com/opht/article/view/658">https://www.ophthalmojournal.com/opht/article/view/658</self-uri><abstract><sec><title>Цель</title><p>Цель: подвести итог пятнадцатилетнего клинического опыта применения ботокса в страбизмологии и определить показания для наиболее эффективного применения хемоденервации в комплексном лечении патологии глазодвигательной системы.</p></sec><sec><title>Пациенты и методы</title><p>Пациенты и методы. Для проведения хемоденервации экстраокулярных мышц был использован препарат ботокс. Оптимальные дозы ботокса при внутримышечном введении составили от 1,25 до 5,0 ед. Выбор дозировки зависит от возраста пациента, вида патологии глазодвигательной системы, степени нарушения мышечной функции и цели проводимого лечения. Лечение было проведено 376 пациентам с различными нарушениями глазодвигательной системы. На момент проведения лечения возраст пациентов составлял от 12 до 78 лет. Инъекция ботокса в экстраокулярные мышцы во всех случаях была первичным методом лечения.</p></sec><sec><title>Результаты</title><p>Результаты. В целом состояние относительного функционального выздоровления было достигнуто в 71,81% случаев (270 пациентов). Лучшие результаты были получены при лечении декомпенсированных гетерофорий, остро возникших гетеротропий, атипичных гетеротропий и первичной гиперфункции нижних косых мышц (в 100% случаев). При этих состояниях у пациентов бинокулярное зрение было сохранным, а дисбаланс глазодвигательной системы не имел выраженных признаков несодружественности. Однако и при лечении пациентов с параличами и парезами черепно-мозговых нервов хемоденервация позволила создать условия для более полного восстановления мышечных функций, избежать возникновения вторичного дисбаланса в глазодвигательной системе. В 70,3% случаев (185 пациентов) не потребовалось последующего хирургического лечения. Достоверные функциональные результаты лечения позволили создать оптимальный алгоритм проведения хемоденервации.</p></sec><sec><title>Заключение</title><p>Заключение. Хемоденервация экстраокулярных мышц является эффективным самостоятельным и дополнительным методом комплексного лечения патологии глазодвигательной системы и расширяет возможности в реабилитации пациентов. Для достижения максимальных функциональных результатов необходим правильный отбор пациентов для проведения этой процедуры с учетом ее целесообразности и преимуществ перед альтернативными методами лечения, выбор оптимальных дозировок препарата ботокс. </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. To summarize our fifteen-years clinical experience of using Botox in strabismology and determine the indications for the most effective use of chemodenervation in the complex treatment of oculomotor system pathology.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. To carry out chemodenervation of extraocular muscles, Botox was used. The optimal dose of Botox for intramuscular injection ranged from 1.25 to 5.0 units. The choice of dosage depends on the patient’s age, the type oculomotor system pathology, the level of muscular dysfunction and the purpose of the treatment. The treatment was performed in 376 patients with various disorders of oculomotor system. At the time of treatment, the patients’ ages ranged from 12 to 78 years. Injection of Botox into the extraocular muscles in all cases was the primary method of treatment.</p></sec><sec><title>Results</title><p>Results. In general, the state of relative functional recovery was achieved in 71.81% of cases (in 270 patients). The best results were obtained in treatment of decompensated heterophories, acute heterotrophies, atypical heterotrophies and primary hyperfunction of the inferior oblique muscles (in 100% of cases). In these conditions, the binocular vision was preserved in patients, and the imbalance of the oculomotor system did not show any sign of incomitance. However, patients with paralysis and paresis of the cranial nerves chemodenervation allowed creating conditions for a more complete restoration of muscular functions, to avoid the occurrence of a secondary imbalance in the oculomotor system. In 70.3% cases (185 patients), subsequent surgical treatment was not required. Reliable functional results of treatment allowed creating the optimal algorithm for chemodenervation.</p></sec><sec><title>Discussion</title><p>Discussion. Chemodenervation of extraocular muscles is an effective independent and additional method of complex treatment of oculomotor system pathology and expands opportunities in patients’ rehabilitation. To achieve maximum functional results, it is necessary to select patients correctly for this procedure, taking into account its appropriateness and advantages over alternative methods of treatment, selection of optimal dosages of Botox. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ботокс</kwd><kwd>хемоденервация</kwd><kwd>косоглазие</kwd><kwd>нистагм</kwd><kwd>патология глазодвигательной системы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Botox</kwd><kwd>chemodenervation</kwd><kwd>strabismus</kwd><kwd>nystagmus</kwd><kwd>pathology of the oculomotor system</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Maya J.F., de Liaño R.G., Catalán M.R., Rayward O. Botulinum toxin treatment in patients up to 3 years of age who have esotropic Duane retraction syndrome. Strabismus. 2013;21:4–7. DOI: 10.3109/09273972.2012.762530</mixed-citation><mixed-citation xml:lang="en">Maya J.F., de Liaño R.G., Catalán M.R., Rayward O. Botulinum toxin treatment in patients up to 3 years of age who have esotropic Duane retraction syndrome. Strabismus. 2013;21:4–7. DOI: 10.3109/09273972.2012.762530</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wan M.J., Mantagos I.S., Shah A.S., Kazlas M., Hunter D.G. Comparison of botulinum toxin with surgery for the treatment of acute-onset comitant esotropia in children. Am J Ophthalmol. 2017;176:33–9. DOI: http://dx.doi.org/10.1016/j. ajo.2016.12.024</mixed-citation><mixed-citation xml:lang="en">Wan M.J., Mantagos I.S., Shah A.S., Kazlas M., Hunter D.G. Comparison of botulinum toxin with surgery for the treatment of acute-onset comitant esotropia in children. Am J Ophthalmol. 2017;176:33–9. DOI: http://dx.doi.org/10.1016/j. ajo.2016.12.024</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ameri A., Mirmohammadsadeghi A., Makateb A., Bazvand F., Hosseini S. Clinical outcomes of botulinum toxin injection in patients with cerebral palsy and esotropia. Strabismus. 2015;23(1):8–13. DOI: 10.3109/09273972.2014.999798</mixed-citation><mixed-citation xml:lang="en">Ameri A., Mirmohammadsadeghi A., Makateb A., Bazvand F., Hosseini S. Clinical outcomes of botulinum toxin injection in patients with cerebral palsy and esotropia. Strabismus. 2015;23(1):8–13. DOI: 10.3109/09273972.2014.999798</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mahan M., Engel J.M. The resurgence of botulinum toxin injection for strabismus in children. Curr Opin Ophthalmol. 2017;28(5):460–4. DOI: 10.1097/ ICU.0000000000000408</mixed-citation><mixed-citation xml:lang="en">Mahan M., Engel J.M. The resurgence of botulinum toxin injection for strabismus in children. Curr Opin Ophthalmol. 2017;28(5):460–4. DOI: 10.1097/ ICU.0000000000000408</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Donahue S.P. Botulinum toxin treatment for esotropia. Am Orthopt J. 2013;63:29– 31. DOI: 10.3368/aoj.63.1.29</mixed-citation><mixed-citation xml:lang="en">Donahue S.P. Botulinum toxin treatment for esotropia. Am Orthopt J. 2013;63:29– 31. DOI: 10.3368/aoj.63.1.29</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Speeg-Schatz C., Burgun P., Gottenkiene S. To what extent may Botulinum toxin type A injections be an alternative choice to surgery in infantile esotropia? Eur J Ophthalmol. 2017;27(3):285–8. DOI: 10.5301/ejo.5000947</mixed-citation><mixed-citation xml:lang="en">Speeg-Schatz C., Burgun P., Gottenkiene S. To what extent may Botulinum toxin type A injections be an alternative choice to surgery in infantile esotropia? Eur J Ophthalmol. 2017;27(3):285–8. DOI: 10.5301/ejo.5000947</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Noguera H., Castiella Acha J.C., Anguiano Jimenez M. Medical and surgical treatment of primary divergent strabismus. Arch Soc Esp Oftalmol. 2014;89(11):431–8. DOI: 10.1016/j.oftal.2014.03.004</mixed-citation><mixed-citation xml:lang="en">Noguera H., Castiella Acha J.C., Anguiano Jimenez M. Medical and surgical treatment of primary divergent strabismus. Arch Soc Esp Oftalmol. 2014;89(11):431–8. DOI: 10.1016/j.oftal.2014.03.004</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Jarrín E., Arranz Márquez E., Yebra González L., García Gil de Bernabé J. Botulinum toxin uses in strabismus: A review of the injections performed during one year in a general hospital. Arch Soc Esp Oftalmol. 2016;91(3):114–9. DOI: 10.1016/j. oftal.2015.11.011</mixed-citation><mixed-citation xml:lang="en">Jarrín E., Arranz Márquez E., Yebra González L., García Gil de Bernabé J. Botulinum toxin uses in strabismus: A review of the injections performed during one year in a general hospital. Arch Soc Esp Oftalmol. 2016;91(3):114–9. DOI: 10.1016/j. oftal.2015.11.011</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Flores-Reyes E.M., Castillo-López M.G., Toledo-Silva R., Vargas-Ortega J., MurilloCorrea C.E., Aguilar-Ruiz A. Botulinum toxin type A as treatment of partially accommodative esotropia. Arch Soc Esp Oftalmol. 2016;91(3):120–4. DOI: 10.1016/j. oftal.2015.11.007</mixed-citation><mixed-citation xml:lang="en">Flores-Reyes E.M., Castillo-López M.G., Toledo-Silva R., Vargas-Ortega J., MurilloCorrea C.E., Aguilar-Ruiz A. Botulinum toxin type A as treatment of partially accommodative esotropia. Arch Soc Esp Oftalmol. 2016;91(3):120–4. DOI: 10.1016/j. oftal.2015.11.007</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Joyce K.E., Beyer F., Thomson R.G., Clarke M.P. A systematic review of the effectiveness of treatments in altering the natural history of intermittent exotropia. Br J Ophthalmol. 2015;99(4):440–50. DOI: 10.1136/bjophthalmol-2013-304627</mixed-citation><mixed-citation xml:lang="en">Joyce K.E., Beyer F., Thomson R.G., Clarke M.P. A systematic review of the effectiveness of treatments in altering the natural history of intermittent exotropia. Br J Ophthalmol. 2015;99(4):440–50. DOI: 10.1136/bjophthalmol-2013-304627</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Issaho D.C., Carvalho F.R.S., Tabuse M.K.U., Carrijo-Carvalho L.C., de Freitas D. The use of botulinum toxin to treat infantile esotropia: a systematic review with meta-analysis. Invest Ophthalmol Vis Sci. 2017;58(12):5468–76. DOI: 10.1167/ iovs.17-22576</mixed-citation><mixed-citation xml:lang="en">Issaho D.C., Carvalho F.R.S., Tabuse M.K.U., Carrijo-Carvalho L.C., de Freitas D. The use of botulinum toxin to treat infantile esotropia: a systematic review with meta-analysis. Invest Ophthalmol Vis Sci. 2017;58(12):5468–76. DOI: 10.1167/ iovs.17-22576</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Rowe F.J., Noonan C.P. Botulinum toxin for the treatment of strabismus. Cochrane Database Syst Rev. 2017;3:CD006499. DOI: 10.1002/14651858.CD006499.pub4</mixed-citation><mixed-citation xml:lang="en">Rowe F.J., Noonan C.P. Botulinum toxin for the treatment of strabismus. Cochrane Database Syst Rev. 2017;3:CD006499. DOI: 10.1002/14651858.CD006499.pub4</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kowal L., Wong E., Yahalom C. Botulinum Toxin in the treatment of strabismus. A review of its use and effects. Disability and Rehabilitation. 2007;29(23):1823–31. DOI: 10.1080/09638280701568189</mixed-citation><mixed-citation xml:lang="en">Kowal L., Wong E., Yahalom C. Botulinum Toxin in the treatment of strabismus. A review of its use and effects. Disability and Rehabilitation. 2007;29(23):1823–31. DOI: 10.1080/09638280701568189</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Özkan S.B. Pearls and pitfalls in the management of Duane syndrome. Taiwan J Ophthalmol. 2017;7:3–11. DOI: 10.4103/tjo.tjo_20_17</mixed-citation><mixed-citation xml:lang="en">Özkan S.B. Pearls and pitfalls in the management of Duane syndrome. Taiwan J Ophthalmol. 2017;7:3–11. DOI: 10.4103/tjo.tjo_20_17</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ozkan S.B., Topaloglu A., Aydin S. The role of botulinum toxin A in augmentation of the effect of recession and/or resection surgery. J AAPOS. 2006;10(2):124–7. DOI: http://dx.doi.org/ 10.1016/j.jaapos.2005.11.011</mixed-citation><mixed-citation xml:lang="en">Ozkan S.B., Topaloglu A., Aydin S. The role of botulinum toxin A in augmentation of the effect of recession and/or resection surgery. J AAPOS. 2006;10(2):124–7. DOI: http://dx.doi.org/ 10.1016/j.jaapos.2005.11.011</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
